Next 10 |
home / stock / tryp:cc / tryp:cc news
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of arrangement (the “...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...
KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangemen...
A look at the top 10 most actives in Canada Argonaut Gold Inc. (AR) rose 1.2% to $0.435 on volume of 5,681,973 shares Toronto-Dominion Bank (The) (TD) fell 0.1% to $78.97 on volume of 5,471,012 shares Vertical Exploration Inc. (VERT) fell 11.1% to $0.04 on volume of 3,613,049 shares Whi...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangeme...
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exoph...
Toronto, Ontario--(Newsfile Corp. - le 5 mars/March 2024) - Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading. The Company has rectified the situation that gave rise to the suspension. _________________________________ Avec effet immédiat, Tryp Therapeut...
Canadian Investment Regulatory Organization Trade Resumption - TRYP Canada NewsWire VANCOUVER, BC , March 5, 2024 /CNW/ - Trading resumes in: Company: Tryp Therpeutics Inc. CSE Symbol: TRYP All Issues: Yes Resumption (ET): 2:15 PM ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Colum...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc. Company Name:
TRYP:CC Stock Symbol:
CNQC Market:
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of arrangement (the “...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...